The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.
X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.
Since 1990, the incidence of hypertension has increased globally, with up to one in three adults worldwide affected by it. Most of those people have no idea they have it. If people could diagnose and monitor hypertension at home, the World Health Organization estimates that up to 76 million lives could be saved with easy fixes, like stopping smoking or adjusting diet.
The actors are reprising their roles from Apple's Mac vs. PC ads playing the personifications of a name brand and the alternative-but now for weight-loss drugs. Long personified Mac in the original Apple campaign by dressing in a more youthful, casual way than Hodgman, who personified a stuffy, dorky PC by wearing glasses and a suit and tie with a closely cropped haircut. (Think Steve Jobs versus Bill Gates.) In the Apple ads, Mac was always portrayed by Long as more cool and capable.
Meta is building a smartwatch, and it wants to know your heart rate, your sleep patterns, your activity levels, and whatever else it can pull from a sensor pressed against your skin all day. The device is codenamed Malibu 2, it's targeting a 2026 launch, and by most accounts it sounds like a perfectly competent health wearable. The problem isn't the hardware. The problem is the company attached to it.
Medtronic ( NYSE: MDT) delivered its strongest enterprise revenue growth in 10 quarters, posting 8.7% reported growth (6.0% organic) for Q3 fiscal 2026. Cardiac Ablation Drives Outperformance The Cardiovascular Portfolio led the quarter with 13.8% reported growth, powered by an exceptional 80% surge in Cardiac Ablation Solutions. U.S. cardiac ablation revenue exploded 137%, driven by the company's pulsed field ablation (PFA) portfolio. Cardiac Rhythm & Heart Failure revenue reached $1.86 billion, up 17%, while Diabetes posted 8.3% organic growth to $796 million.
Whenever medical AI handles anything with medium to high risk, you want regulation: internal self-regulation or external governmental regulation. It's mostly been internal thus far, and there are differences in how each hospital system validates, reviews, and monitors healthcare AI. When done on a hospital-by-hospital basis like this, costs to do this kind of evaluation and monitoring can be significant, which means some hospitals can do this, and some can't.
Emma Dyer remembers the moment she clicked "buy now" on a set of weightloss jabs she found online. She had no medical consultation, no ID checks, and no questions about her history of anorexia and bulimia. "It was just so easy - too easy," she says. "They never asked for my medical history or what medication I was taking. It was like buying groceries."